MTOR expression and prognosis in elderly patients with laryngeal carcinoma: Uni- and multivariate analyses

Oral Oncology

Volumn 48, Issue 6, 2012, Pages 530-534

  Marioni, Gino ^a   Staffieri, Alberto ^a   Lora, Lucia ^a   Fermo, Salvatore ^a   Giacomelli, Luciano ^a   La Torre, Fabio Biagio ^a   Favaretto, Niccolò ^a   Valentini, Elisa ^a   Manzato, Enzo ^a,b   Blandamura, Stella ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b CNR   (Italy)

Author keywords

Elderly patients; Laryngeal carcinoma; mTOR; Multivariate analysis; Prognosis; Targeted therapy

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LARYNGEAL NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84861610674     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2012.01.002     Document Type: Article

References (23)

1. K.N. Syrigos, D. Karachalios, E.M. Karapanagiotou, C.M. Nutting, L. Manolopoulos, and K.J. Harrington Head and neck cancer in the elderly: an overview on the treatment modalities Cancer Treat Rev 35 2009 237 245
2. A.P. Silveira, J. Gonçalves, T. Sequeira, C. Ribeiro, C. Lopes, and E. Monteiro Geriatric oncology: comparing health related quality of life in head and neck cancer patients Head Neck Oncol 3 2011 3
3. L. Balducci, and W.B. Ershler Cancer and ageing: a nexus at several levels Nat Rev Cancer 5 2005 655 662
4. M.M. Mita, A. Mita, and E.K. Rowinsky The molecular target of rapamycin (mTOR) as a therapeutical target against cancer Cancer Biol Ther 2 2003 S169 S177
5. A.S. Strimpakos, E.M. Karapanagiotou, M.W. Saif, and K.N. Syrigos The role of mTOR in the management of solid tumors: an overview Cancer Treat Rev 35 2009 148 159
6. J.E. Dancey Therapeutic targets: MTOR and related pathways Cancer Biol Ther 5 2006 1065 1073
7. Y.M. Liao, C. Kim, and Y. Yen Mammalian target of rapamycin and head and neck squamous cell carcinoma Head Neck Oncol 3 2011 22
8. G. Yu, J. Wang, Y. Chen, X. Wang, J. Pan, and G. Li Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer Clin Cancer Res 15 2009 1821 1829
9. E. Dazert, and M.N. Hall mTOR signaling in disease Curr Opin Cell Biol 23 2011 744 755
10. D.E. Harrison, R. Strong, Z.D. Sharp, J.F. Nelson, C.M. Astle, and K. Flurkey Rapamycin fed late in life extends lifespan in genetically heterogeneous mice Nature 460 2009 392 395
11. V.N. Anisimov, M.A. Zabezhinski, I.G. Popovich, T.S. Piskunova, A.V. Semenchenko, and M.L. Tyndyk Rapamycin extends maximal lifespan in cancer-prone mice Am J Pathol 176 2010 2092 2097
12. G. Marioni, R. Marchese-Ragona, G. Cartei, F. Marchese, and A. Staffieri Current opinion in diagnosis and treatment of laryngeal carcinoma Cancer Treat Rev 32 2006 504 515
13. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 7th edition Oxford: Wiley-Blackwell. 2009.
14. L. Balducci, G. Colloca, M. Cesari, and G. Gambassi Assessment and treatment of elderly patients with cancer Surg Oncol 19 2010 117 123
15. C. Clark, S. Shah, L. Herman-Ferdinandez, O. Ekshyyan, F. Abreo, and X. Rong Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients Laryngoscope 120 2010 1159 1165
16. G. Marioni, A. Staffieri, L. Giacomelli, M. Lionello, V. Guzzardo, and A. Busnardo Mammalian target of rapamycin (mTOR) expression and laryngeal squamous cell carcinoma prognosis: novel preliminary evidence Histopathology 58 2011 1148 1156
17. Lionello M, Blandamura S, Loreggian L, Ottaviano G, Giacomelli L, Marchese-Ragona R, et al. High mTOR expression is associated with a worse oncological outcome in laryngeal carcinoma after postoperative radiotherapy: a pilot study. J Oral Pathol Med 2011 Sept 22 [Epub ahead of print].
18. K. Hirashima, Y. Baba, M. Watanabe, R. Karashima, N. Sato, and Y. Imamura Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma Ann Surg Oncol 17 2010 2486 2493
19. H. Zhou, Y. Luo, and S. Huang Updates of mTOR inhibitors Anticancer Agents Med Chem 10 2010 571 581
20. E. Caron, S. Ghosh, Y. Matsuoka, D. Ashton-Beaucage, M. Therrien, and S. Lemieux A comprehensive map of the mTOR signaling network Mol Syst Biol 6 2010 453
21. A.S. Don, and X.F. Zheng Recent clinical trials of mTOR-targeted cancer therapies Rev Recent Clin Trials 6 2011 24 35
22. E.T. Shinohara, A. Maity, N. Jha, and R.A. Lustig Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck Head Neck 31 2009 406 411
23. O. Ekshyyan, G.M. Mills, T. Lian, N. Amirghahari, X. Rong, and M. Lowery-Nordberg Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma Head Neck 32 2010 1619 1628